Foresite Capital Management IV, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Foresite Capital Management IV, LLC reported 5 stock positions worth $111.1 million. Its top holding was Pharvaris (PHVS) at 62.3% of the portfolio, followed by Maze Therapeutics (MAZE, 20.9%) and Lyell Immunopharma (LYEL, 7.8%). Compared with Q4 2024, it opened 1 new position, added to 2 and reduced 1. The biggest buy was a new position in Maze Therapeutics (MAZE) and the biggest sale Kura Oncology (KURA, shares −36%).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $111.1M (Q1 2025)
- SEC Filing
- 0001104659-25-049390 ↗ filed May 15, 2025
Holdings Value
Holdings 5 stocks · $111.1M
Portfolio Sells Q4 2024 → Q1 2025
| KURA Kura Oncology Inc. | Reduce -35.6% | 6.61% | −7.22 |
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |